Outlook Therapeutics, Inc.
OTLK
$0.38
$0.037.87%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -1,215.69% | -106.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -1,215.69% | -106.10% | |||
| Cost of Revenue | -46.86% | -8.97% | |||
| Gross Profit | 30.27% | -15.12% | |||
| SG&A Expenses | -16.61% | 6.69% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -28.72% | -0.18% | |||
| Operating Income | 22.12% | -9.94% | |||
| Income Before Tax | -55.30% | 26.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -73.46% | 34.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -73.46% | 34.04% | |||
| EBIT | 22.12% | -9.94% | |||
| EBITDA | 22.16% | -9.96% | |||
| EPS Basic | -35.96% | 48.34% | |||
| Normalized Basic EPS | 11.86% | 36.25% | |||
| EPS Diluted | -35.29% | 48.53% | |||
| Normalized Diluted EPS | 11.86% | 36.25% | |||
| Average Basic Shares Outstanding | 27.57% | 27.70% | |||
| Average Diluted Shares Outstanding | 27.57% | 27.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||